Nature Communications (May 2019)

Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection

  • Jessica Radzio-Basu,
  • Olivia Council,
  • Mian-er Cong,
  • Susan Ruone,
  • Alicia Newton,
  • Xierong Wei,
  • James Mitchell,
  • Shanon Ellis,
  • Christos J. Petropoulos,
  • Wei Huang,
  • William Spreen,
  • Walid Heneine,
  • J. Gerardo García-Lerma

DOI
https://doi.org/10.1038/s41467-019-10047-w
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 8

Abstract

Read online

Long-acting formulation of the integrase inhibitor cabotegravir (CAB LA) is in clinical development for HIV pre-exposure prophylaxis (PrEP). Here, using a SHIV macaque model, the authors show emergence of integrase mutations associated to CAB LA PrEP that confer pan-integrase inhibitor resistance.